Identification
- Generic Name
- Cycrimine
- DrugBank Accession Number
- DB00942
- Background
Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cycrimine (DB00942)
- Weight
- Average: 287.4397
Monoisotopic: 287.224914555 - Chemical Formula
- C19H29NO
- Synonyms
- (±)-cycrimine
- alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol
- Cicrimina
- Cycrimine
- Cycriminum
Pharmacology
- Indication
For treatment and management of Parkinson's disease.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Cycrimine is a central anticholenergic used in the treatment of the symptoms of Parkinson's disease. It is a drug used to reduce levels of acetylcholine. Acetylcholine is usually in balance with dopamine neurotransmitters, however lower levels of dopamine are present in the brain of patients suffering from Parkinson's disease. By lowering levels of acetylcholine, it is thought that this balance may be restored.
- Mechanism of action
Cycrimine binds the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of Parkinson's disease.
Target Actions Organism AMuscarinic acetylcholine receptor M1 antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
14-21%
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAclidinium The risk or severity of adverse effects can be increased when Cycrimine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Cycrimine. Alfentanil The risk or severity of adverse effects can be increased when Cycrimine is combined with Alfentanil. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Cycrimine. Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Cycrimine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cycrimine hydrochloride 9RB4L4K895 126-02-3 WBCWFMFZMRFRLT-UHFFFAOYSA-N - International/Other Brands
- Pagitane (Lilly)
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Aralkylamines
- Alternative Parents
- Piperidines / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,3-aminoalcohol / Alcohol / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxygen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, tertiary alcohol, tertiary amino compound (CHEBI:59692)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 543567RFQQ
- CAS number
- 77-39-4
- InChI Key
- SWRUZBWLEWHWRI-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
- IUPAC Name
- 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
- SMILES
- OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1
References
- Synthesis Reference
Ruddy, A.W. and Becker, T.J.; U.S. Patent 2,680,115; June 1, 1954; assigned to Winthrop-Stearns Inc.
- General References
- Vedasiromoni JR, Ganguly DK: Cycrimine on rat diaphragm. Arch Int Pharmacodyn Ther. 1976 Jan;219(1):64-9. [Article]
- External Links
- Human Metabolome Database
- HMDB0015077
- PubChem Compound
- 2911
- PubChem Substance
- 46506736
- ChemSpider
- 2808
- 22037
- ChEBI
- 59692
- ChEMBL
- CHEMBL1201227
- Therapeutic Targets Database
- DAP001120
- PharmGKB
- PA164749387
- Wikipedia
- Cycrimine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Eli lilly and co
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 112-113 Ruddy, A.W. and Becker, T.J.; U.S. Patent 2,680,115; June 1, 1954; assigned to Winthrop-Stearns Inc. logP 4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00909 mg/mL ALOGPS logP 4.15 ALOGPS logP 3.79 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 13.84 Chemaxon pKa (Strongest Basic) 9.32 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 23.47 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 88.6 m3·mol-1 Chemaxon Polarizability 34.79 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9465 Blood Brain Barrier + 0.9686 Caco-2 permeable + 0.6502 P-glycoprotein substrate Substrate 0.654 P-glycoprotein inhibitor I Inhibitor 0.5407 P-glycoprotein inhibitor II Non-inhibitor 0.8279 Renal organic cation transporter Inhibitor 0.7739 CYP450 2C9 substrate Non-substrate 0.8273 CYP450 2D6 substrate Non-substrate 0.8337 CYP450 3A4 substrate Non-substrate 0.5554 CYP450 1A2 substrate Non-inhibitor 0.9193 CYP450 2C9 inhibitor Non-inhibitor 0.9181 CYP450 2D6 inhibitor Inhibitor 0.9056 CYP450 2C19 inhibitor Non-inhibitor 0.9102 CYP450 3A4 inhibitor Non-inhibitor 0.8257 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9336 Ames test Non AMES toxic 0.856 Carcinogenicity Non-carcinogens 0.9292 Biodegradation Not ready biodegradable 0.9172 Rat acute toxicity 2.7260 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.6253 hERG inhibition (predictor II) Inhibitor 0.5169
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 180.1279682 predictedDarkChem Lite v0.1.0 [M-H]- 167.00693 predictedDeepCCS 1.0 (2019) [M+H]+ 180.0758682 predictedDarkChem Lite v0.1.0 [M+H]+ 169.36493 predictedDeepCCS 1.0 (2019) [M+Na]+ 180.1584682 predictedDarkChem Lite v0.1.0 [M+Na]+ 175.45808 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Vedasiromoni JR, Ganguly DK: Cycrimine on rat diaphragm. Arch Int Pharmacodyn Ther. 1976 Jan;219(1):64-9. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 02, 2024 22:46